Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study - Wikidata - wikimedia - TriplyDB

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

http://www.wikidata.org/entity/Q35349653

about

Quality of life and hepatocellular carcinoma Systemic therapy of hepatocellular carcinoma: current status and future perspectives DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis Clinical outcomes of compensated and decompensated cirrhosis: A long term study.Systemic chemotherapy of liver tumors.Primary liver tumors.The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Hepatocellular carcinoma--cause, treatment and metastasis.Hepatocellular carcinoma: is current therapy really altering outcome?Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.Non-surgical treatment of hepatocellular carcinoma.Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases.Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity Somatostatin analogs and radiopeptides in cancer therapy.Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells.Promoter hypermethylation-related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer.Octreotide in Palliative Treatment of Hepatic Metastases: Is it Effective for Clinical Stabilization?Hepatocellular carcinoma: are we making progress?Regulatory peptide receptors in human hepatocellular carcinomas.Pharmacotherapy of hepatocellular carcinoma.Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma.The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma Systemic therapies for hepatocellular carcinoma.Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment.Treatment options for hepatocellular carcinoma.Update on new approaches in the management of hepatocellular carcinoma.Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia.Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.New agonist- and antagonist-based treatment approaches for advanced prostate cancer.Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now.Assessment of treatment response in hepatocellular carcinoma: a review of the literature.Octreotide in Palliative Treatment of Unresectable Cholangiocarcinoma: Is it Effective for Disease Stabilization?

P2860

Q26825504-3DBAEC15-7AEE-45C9-8B15-C9FD5C2A3327 Q26865844-EBA60278-356B-4368-AB55-46A60B17E763 Q28484901-1477F398-FD45-4144-B7DC-3FCBA2113F92 Q33948229-6703BE47-21CB-431F-865E-B66BAC004F0B Q34110952-FB0E331C-98A7-45E7-A66C-613C28DC2521 Q34110964-19183919-9B3D-44B6-B13F-DB41DDE7FC73 Q34182483-E73A5159-1B50-4C5D-B740-3847DFCF7573 Q34512068-661617FF-08E0-4B84-8336-9906EDC624C7 Q34527230-AA5EAF3A-F644-4FB9-8A29-25F3B21DE621 Q34532749-113925C0-12B8-4F6B-8466-F3C790951320 Q34539241-C0C4FD29-51CE-42F3-9443-D1725C4EAF58 Q34563336-D11B9246-A38D-4CDD-9799-D3E53C197D2A Q34832716-022690FA-938E-40DD-AF86-B0B3E3158AD8 Q34972896-1F045E8F-49FD-4E51-8E77-446492D1818B Q35046099-DB9B6CCA-5456-427E-9FC4-6FE562E2D0CA Q35130509-EE142DE0-CCF7-48B1-8BF3-65481220581A Q35181001-AA111AE9-8B65-4963-B5F0-53A35675165E Q35193283-458B4621-63C7-4108-8106-A2BF0348DA72 Q35357724-E8AF42D2-D706-4391-BFDD-B0083496151A Q35593957-2A886CCF-9073-4C34-802E-39F8DC5921B1 Q35594730-345EEBB6-66A6-4071-B3B2-734A33E37F77 Q35614440-96B1B8AA-8A0A-47B7-9500-9C341AD23B76 Q35621231-8E71F0A4-344A-4C0D-8643-0624D5FEFAD4 Q35806395-F0B657D2-9E37-46A9-8BC3-5C423F562D19 Q35964708-02ED7ABD-68C6-48E4-904E-56206228E73D Q36474555-9DF9163E-84A4-4BA7-ACDF-AA1D32D1945F Q36611050-528D3451-FD6B-4109-8A0E-F2A29ED5396C Q36611703-E2E0A7DE-8A14-4AF1-A015-915959808FB8 Q37198606-C307CDAB-AE43-42D0-BE2C-5D2D6647FD43 Q37211764-C6543F94-3D5C-45CE-ABC4-D9CD0EE08CA8 Q37345911-E9C3BC9B-43A0-46F7-B183-D7BA27E9D32E Q37356150-E8CC5A2B-C1AA-44DD-844C-8B02D00A1975 Q37426913-D6E6FEB8-4241-4EDA-8429-5AE6ADD6E0B6 Q37579225-924764D8-5547-4E6E-9F44-6036EB2D9F81 Q37622928-0A76BC22-5839-4795-A621-148D428F2799 Q37908974-80A77AB7-EBE6-45D9-BC61-F76EFFFC3A5D Q38042768-E1C23D33-EC50-4F58-B585-8CAB0F229E16 Q38056849-F3D900A7-B0CB-4FDB-906E-998C5DEBCE40 Q38110321-5B8A8C78-D42D-4B25-9606-7F32A763CF29 Q38260593-B740A622-477E-4882-8E2E-49544A3B0650

P2860

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

http://www.wikidata.org/entity/Q35349653

description

1998 nî lūn-bûn

@nan

1998 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի մարտին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

@ast

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

@en

type

label

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

@ast

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

@en

prefLabel

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

@ast

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

@en

P1433

Q35349653-60626666-7E84-49BF-B2CA-CEA81762DFBD

P1476

Q35349653-411B4839-2754-4DBD-99E5-E3189873B4CF

P2093

Q35349653-58A9C5DB-08E1-4005-ABFD-231FD43B7D65

Q35349653-5F39F2E5-4B7C-4B72-8111-854DD5EE6ECB

Q35349653-6F245015-3036-4AAE-B73D-7C0C7FA21448

Q35349653-901FC9EB-9E46-4A8F-8D57-21D7D6DB39AB

Q35349653-C182BB24-9898-4DB5-ABF8-8E5A510ABF4E

Q35349653-E5D417C2-CF0E-4B16-B54D-981BD48B22E7

P2860

Q35349653-1A9E851E-9278-4C61-8BE6-6EB5A9562C82

Q35349653-1BABFE61-DEFF-485A-8D6E-050F3AD241A0

Q35349653-1E91B6B5-1980-42DD-B603-2F91A483D974

Q35349653-28214636-BB17-42E7-8A57-160A4702B49C

Q35349653-36031FCB-1CE7-4412-882F-283D60A8835C

Q35349653-4A748C2F-16F1-4696-A5BE-019305AE13AA

Q35349653-4EB975F2-4F22-487E-80C4-D3B1E7005C37

Q35349653-55941386-02C3-4E61-B747-9F8FA2EB6A0B

Q35349653-5850D593-8333-4F7F-8A84-2A0819AAB294

Q35349653-69DC6C65-EC9E-4429-AA4F-F9B04FF955A2

P304

Q35349653-B68387FD-7003-4B8B-A1D8-ADDB8D8FDF2F

P31

Q35349653-B473C7F8-6C3D-480F-A8C4-F9E7BD98195D

P356

Q35349653-9077B80F-817F-4660-977F-C34C5F399B73

P407

Q35349653-C464B9F0-012C-4594-86AF-5E5AEDB651FA

P433

Q35349653-73616849-6663-4863-8A3B-D8EFCAFA2930

P478

Q35349653-2D364580-B414-4265-8DCD-74D61CC488BB

P577

Q35349653-132CDEE0-C9E4-4EDD-93AA-FAD1031235C1

P5875

Q35349653-4A2B54D1-589D-490C-944C-C02EC77AA515

P698

Q35349653-D612CE6E-3A07-45D4-82C3-73BB6F72ED23

P932

Q35349653-29F0707A-502D-48E8-B84A-966670D6AE3F

P356

P1433

P1476

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

@en

P2093

Kouroumalis E

http://www.w3.org/2001/XMLSchema#string

Manousos ON

http://www.w3.org/2001/XMLSchema#string

Moschandrea J

http://www.w3.org/2001/XMLSchema#string

Skordilis P

http://www.w3.org/2001/XMLSchema#string

Thermos K

http://www.w3.org/2001/XMLSchema#string

Vasilaki A

http://www.w3.org/2001/XMLSchema#string

P2860

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.

Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.

Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma.

The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

Distribution of somatostatin receptors in normal and tumor tissue.

Oncological applications of somatostatin analogues.

Hepatitis B and primary hepatocellular carcinoma in a European population.

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.

P304

442-447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.42.3.442

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

1998-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13707268

http://www.w3.org/2001/XMLSchema#string

P698

9577356

http://www.w3.org/2001/XMLSchema#string

P932

1727020

http://www.w3.org/2001/XMLSchema#string